Celcuity (CELC) Saham Harga
Celcuity Harga
Target harga median analis adalah 155,00 USD, di atas harga saat ini sebesar 124,2%. Dari 18 analis, 17 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Celcuity
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Celcuity
Pertanyaan yang sering diajukan tentang saham Celcuity
Celcuity Inc, a targeted diagnostics company, operates on a unique business model focusing on developing and commercializing novel companion diagnostic tests. By analyzing a patient's living cancer cells used in diagnostic testing, Celcuity gathers crucial data to identify abnormal signaling pathways that can guide physicians in selecting the most effective treatment. Leveraging its proprietary CELsignia platform, Celcuity aims to improve patient outcomes by enabling the identification of patients who are likely to respond favorably to specific targeted therapies. Through its innovative approach, Celcuity strives to revolutionize personalized medicine in the field of cancer diagnostics.
Celcuity Inc is primarily active in the biotechnology industry.
The main competitors of Celcuity Inc in the market are large pharmaceutical companies such as Pfizer, Novartis, and Roche.
Celcuity Inc is a biotechnology company based in Minneapolis, Minnesota. Founded in 2012, Celcuity focuses on developing innovative therapeutic solutions for the treatment of cancer. The company specializes in discovering cancer subtypes by analyzing a patient's cells to identify abnormal signaling activity. By providing this personalized information, Celcuity aims to help healthcare professionals make more informed treatment decisions. With its cutting-edge platform and collaborations with renowned institutions, Celcuity Inc is committed to advancing precision medicine and improving patient outcomes in the field of oncology.
Celcuity Inc has achieved several significant milestones in its journey. The company has made remarkable progress in the field of precision medicine and oncology diagnostics. One of the notable achievements includes its successful initial public offering (IPO), which helped to raise funds for further research and development efforts. Moreover, Celcuity has successfully established collaborations with renowned academic institutions and pharmaceutical companies, allowing for the expansion of its product pipeline and access to a broader patient population. The continued advancements in their proprietary CELsignia platform have also provided valuable insights into the molecular signatures of various cancers, enhancing physicians' ability to personalize treatment strategies.
Celcuity Inc is primarily present in the United States.
Celcuity Inc represents the values of innovation, precision, and patient-centered care. As a biotechnology company, Celcuity is dedicated to developing and commercializing novel diagnostic tests to identify and treat cancer patients who can benefit from targeted therapies. Their corporate philosophy emphasizes the importance of using cutting-edge technology to improve patient outcomes and provide physicians with precise and actionable information. By harnessing the power of CELsignaling™, Celcuity strives to revolutionize therapeutic decision-making in oncology. Through their relentless pursuit of scientific advancements, Celcuity Inc aims to make a significant and positive impact in the field of precision medicine.
Analis saat ini menetapkan target harga rata-rata 154,33 USD untuk saham Celcuity (median: 155,00 USD), yaitu +122,2 % terhadap harga terbaru. Konsensus didasarkan pada 18 peringkat analis.
18 analis saat ini menilai saham Celcuity: 17 merekomendasikan beli, 1 tahan, dan 0 jual. Untuk 2026, analis memperkirakan Celcuity menghasilkan pendapatan 23,34 Juta. USD dan laba per saham -3,86 USD.
Dengan kurs saat ini, saham Celcuity diperdagangkan pada 61,94 EUR (69,13 USD).
Saham Celcuity (CELC) tercatat di 1 bursa, termasuk: NASDAQ (CELC).
Celcuity Inc is a US biotechnology company specializing in the development of precision medicine solutions for the treatment of cancer. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota. Celcuity operates in two business areas: drug development and diagnostic test development. Celcuity's drug development is based on the discovery of new mechanistic target molecules that play a role in cancer formation. The company is working intensively to develop drugs that specifically target these targets to achieve better efficacy and tolerability in cancer therapy. The second business area is the development of diagnostic tests. Celcuity has developed a novel diagnostic procedure that identifies the molecular signature of cancer cells, enabling rapid and targeted diagnosis. These tests can help identify patient groups most likely to benefit from specific cancer treatments, leading to better and personalized therapies. Celcuity already offers various diagnostic tests, including the CELx HER2 Signaling Function Test, which measures the HER2 signaling pathway in tumor cells, allowing prediction of the efficacy of various HER2-targeted therapies. Celcuity's business model is based on the development of innovative solutions based on precision medicine approaches. The company collaborates with renowned research institutions and pharmaceutical companies. Celcuity is a publicly traded company financed through the sale of shares. The company has invested significantly in research and development in recent years and has acquired several patents to protect its technology. Celcuity aims to improve the lives of cancer patients through the development of better treatment options and a personalized approach. Collaboration with the medical community and the development of innovative diagnostic tests are key priorities. Overall, Celcuity is a promising biotechnology company leading in the field of precision medicine for cancer therapy. The company has made significant progress in recent years and is committed to revolutionizing cancer therapy through the provision of personalized treatments.
Pendapatan diperkirakan dari Celcuity adalah 23,34 Juta. USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Celcuity adalah -202,73 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Celcuity saat ini adalah -17,92. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Celcuity.
Rasio harga-terhadap-penjualan (PSR) Celcuity saat ini adalah 155,62. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Celcuity.
Skor Kualitas AlleAktien untuk Celcuity adalah 4/10.
ISIN dari Celcuity adalah US15102K1007. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Celcuity adalah A2JAAX. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Celcuity adalah CELC. Simbol ticker digunakan untuk memperdagangkan saham Celcuity di bursa saham.
Saham Celcuity
Kelompok Peer Celcuity
Celcuity Ticker
Celcuity FIGI
Semua metrik fundamental dan analisis mendalam Celcuity
Analisis saham kami untuk saham Celcuity mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Celcuity. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.